VGI Health Technology (XNEC:VTL) Capital Expenditure : A$0.00 Mil (TTM As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

VGI Health Technology's cash flow for capital expenditures for the six months ended in . 20 was A$0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in . 20 was A$0.00 Mil.

VGI Health Technology Capital Expenditure Historical Data

The historical data trend for VGI Health Technology's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Capital Expenditure Chart

VGI Health Technology Annual Data

Trend

Capital Expenditure

VGI Health Technology Semi-Annual Data

Capital Expenditure

VGI Health Technology Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Capital Expenditure for the trailing twelve months (TTM) ended in . 20 was A$0.00 Mil.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines